Giant-cell tumour

Mazabraud, A

doi:10.1007/978-3-642-95839-7_21

Cited by 2 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,12,13 According to the World Health Organization classification of soft tissue and bone tumours in 2020, GCTB was changed from a benign to an intermediate malignant tumour with locally aggressive behaviour and a high recurrence rate in humans. 14 Histologically benign pulmonary metastases occasionally occur in humans (1-9%). 13,15,16 Rarely, GCTB may undergo malignant transformation.…”

Section: Discussionmentioning

confidence: 99%

“…Histologically, GCTBs have three main components: ovoid-to-spindle-shaped mononuclear stromal cells with a monotonous appearance; osteoclast-like multinucleated giant cells; and mononuclear cells of the monocyte/ macrophage lineage. 11,14,39 The mononuclear stromal cells are believed to be derived from the osteoblast lineage and are the neoplastic component of the tumour. 18,40,41 The giant cells in this tumour are labelled with Iba1.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vertebral giant cell tumour of bone in a domestic shorthair cat

Carrete¹,

Tabanez²,

Civello³

et al. 2023

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summary A 10-year-old male neutered domestic shorthair cat was presented with a 5-month history of progressive non-ambulatory paraparesis. Initial vertebral column radiographs revealed an L2–L3 expansile osteolytic lesion. Spinal MRI showed a well-demarcated, compressive expansile extradural mass lesion affecting the caudal lamina, caudal articular processes and right pedicle of the second lumbar vertebra. The mass was hypointense/isointense on T2-weighted images, isointense on T1-weighted images and had mild homogeneous contrast enhancement after gadolinium administration. MRI of the remaining neuroaxis and CT of the neck, thorax and abdomen with ioversol contrast revealed no additional neoplastic foci. The lesion was removed by en bloc resection via a dorsal L2–L3 laminectomy, including the articular process joints and pedicles. Vertebral stabilisation was performed with titanium screws placed within L1, L2, L3 and L4 pedicles with polymethylmethacrylate cement embedding. Histopathology revealed an osteoproductive neoplasm composed of spindle and multinucleated giant cells without detectable cellular atypia or mitotic activity. On immunohistochemical evaluation, osterix, ionised calcium-binding adaptor molecule 1 and vimentin labelling were observed. Based on the clinical and histological features, a giant cell tumour of bone was considered most likely. Follow-up at 3 and 24 weeks postoperatively demonstrated significant neurological improvement. Postoperative full-body CT at 6 months showed instability of the stabilisation construct but absence of local recurrence or metastasis. Relevance and novel information This is the first reported case of a giant cell tumour of bone in the vertebra of a cat. We present the imaging findings, surgical treatment, histopathology, immunohistochemistry and outcome of this rare neoplasm.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Vertebral giant cell tumour of bone in a domestic shorthair cat

Carrete¹,

Tabanez²,

Civello³

et al. 2023

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

show abstract

“…Giant cell tumour of bone (GCTB) is a rare, benign, and locally aggressive primary bone neoplasm that accounts for up to 5% of all bone tumours [1]. Rarely, GCTB reveals malignant behaviour.…”

Section: Introductionmentioning

confidence: 99%

Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre

Vari

Riva

Onesti

et al. 2022

IJMS

View full text Add to dashboard Cite

Giant cell tumour of bone (GCTB) is a benign, locally aggressive primary bone neoplasm that represents 5% of all bone tumours. The principal treatment approach is surgery. Although generally GCTB is considered only a locally aggressive disease, it can metastasise, and lung metastases occur in 1–9% of patients. To date, only the use of denosumab has been approved as medical treatment for GCTB. Even more rarely, GCTB undergoes sarcomatous transformation into a malignant tumour (4% of all GCTB), but history of this malignant transformation is unclear and unpredictable. Considering the rarity of the event, the data in the literature are few. In this review, we summarise published data of GCTB malignant transformation and we analyse three cases of malignant transformation of GCTB, evaluating histopathology, genetics, and radiological aspects. Despite the rarity of this event, we conclude that a strict follow up is recommended to detect early malignant transformation.

show abstract

Giant-cell tumour

Cited by 2 publications

References 59 publications

Vertebral giant cell tumour of bone in a domestic shorthair cat

Vertebral giant cell tumour of bone in a domestic shorthair cat

Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre

Contact Info

Product

Resources

About